Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.62
-0.12 (-0.49%)
Jun 24, 2025, 4:00 PM - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 9 analysts that cover Pacira BioSciences stock have a consensus rating of "Buy" and an average price target of $29.89, which forecasts a 21.41% increase in the stock price over the next year. The lowest target is $10 and the highest is $65.
Price Target: $29.89 (+21.41%)
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +21.85% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +29.98% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +164.01% | Apr 8, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $24 | Buy | Maintains | $17 → $24 | -2.52% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +29.98% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
753.84M
from 700.97M
Increased by 7.54%
Revenue Next Year
835.12M
from 753.84M
Increased by 10.78%
EPS This Year
2.81
from -2.15
EPS Next Year
3.35
from 2.81
Increased by 19.14%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 792.7M | 897.2M | 995.8M | ||
| Avg | 753.8M | 835.1M | 916.0M | ||
| Low | 715.9M | 787.2M | 808.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.1% | 19.0% | 19.2% | ||
| Avg | 7.5% | 10.8% | 9.7% | ||
| Low | 2.1% | 4.4% | -3.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.56 | 4.13 | 5.38 | ||
| Avg | 2.81 | 3.35 | 4.29 | ||
| Low | 2.05 | 2.99 | 3.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 47.1% | 60.8% | ||
| Avg | - | 19.1% | 28.0% | ||
| Low | - | 6.4% | 0.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.